<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>362</serviceExecutionTime><Drug id="69855"><DrugName>ligelizumab</DrugName><DrugNamesKey><Name id="42983806">ligelizumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>ligelizumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>QGE-031</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20318">Tanox Inc</CompanyOriginator><CompaniesPrimary><Company id="23137">Novartis AG</Company></CompaniesPrimary><CompaniesSecondary><Company id="20318">Tanox Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="69855" type="Drug"><TargetEntity id="721341" type="siDrug">Ligelizumab</TargetEntity></SourceEntity><SourceEntity id="20318" type="Company"><TargetEntity id="4295916041" type="organizationId">Tanox Inc</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="1005" type="ciIndication"><TargetEntity id="4148" type="siCondition"/><TargetEntity id="1570" type="siCondition"/></SourceEntity><SourceEntity id="1102" type="ciIndication"><TargetEntity id="L20" type="ICD10"/><TargetEntity id="691" type="ICD9"/><TargetEntity id="10012438" type="MEDDRA"/><TargetEntity id="D003876" type="MeSH"/><TargetEntity id="-1439185598" type="omicsDisease"/><TargetEntity id="456" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="340" type="ciIndication"><TargetEntity id="L50" type="ICD10"/><TargetEntity id="10046735" type="MEDDRA"/><TargetEntity id="D014581" type="MeSH"/><TargetEntity id="-97820952" type="omicsDisease"/><TargetEntity id="448" type="siCondition"/></SourceEntity><SourceEntity id="3612" type="ciIndication"><TargetEntity id="10016946" type="MEDDRA"/><TargetEntity id="D005512" type="MeSH"/><TargetEntity id="-291885503" type="omicsDisease"/><TargetEntity id="1183" type="siCondition"/></SourceEntity><SourceEntity id="3615" type="ciIndication"><TargetEntity id="D021183" type="MeSH"/><TargetEntity id="-114525935" type="omicsDisease"/><TargetEntity id="4238" type="siCondition"/></SourceEntity><SourceEntity id="6187" type="ciIndication"><TargetEntity id="L12.0" type="ICD10"/><TargetEntity id="D010391" type="MeSH"/><TargetEntity id="703" type="ORPHANET"/><TargetEntity id="-1315177552" type="omicsDisease"/><TargetEntity id="1994" type="siCondition"/></SourceEntity><SourceEntity id="1747" type="Action"><TargetEntity id="4322" type="Mechanism">Anti-IgE (Fc Region)</TargetEntity><TargetEntity id="3700" type="Mechanism">Anti-IgE</TargetEntity><TargetEntity id="1112" type="Mechanism">Immunoglobulin E (IgE) Production Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="340">Urticaria</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1005">Unidentified indication</Indication><Indication id="1102">Atopic dermatitis</Indication><Indication id="31">Asthma</Indication><Indication id="3612">Food hypersensitivity</Indication><Indication id="3615">Peanut hypersensitivity</Indication><Indication id="6187">Bullous pemphigoid</Indication></IndicationsSecondary><ActionsPrimary><Action id="1747">Immunoglobulin E antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2019-07-01T12:56:02.000Z</LastModificationDate><ChangeDateLast>2019-07-02T00:00:00.000Z</ChangeDateLast><AddedDate>2011-01-28T17:43:39.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, under license from &lt;ulink linkID="20318" linkType="Company"&gt;Tanox&lt;/ulink&gt; [&lt;ulink linkID="1164321" linkType="Reference"&gt;1164321&lt;/ulink&gt;], is developing ligelizumab (QGE-031), a high-affinity  anti-IgE monoclonal antibody, for the potential sc treatment of urticaria  [&lt;ulink linkID="1730053" linkType="Reference"&gt;1730053&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, two phase III trials (PEARL1 and PEARL2) were initiated in patients with chronic spontaneous urticaria [&lt;ulink linkID="2090844" linkType="Reference"&gt;2090844&lt;/ulink&gt;], [&lt;ulink linkID="2053168" linkType="Reference"&gt;2053168&lt;/ulink&gt;], [&lt;ulink linkID="2101443" linkType="Reference"&gt;2101443&lt;/ulink&gt;]. In January 2018, filings for chronic spontaneous or idiopathic urticaria were expected in 2021 [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]; in January 2019, this was still the case [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novartis was also previously investigating the antibody for peanut allergy; in March 2012, a phase II peanut allergy trial was planned to begin  in May 2012. However, the trial was withdrawn prior to patient enrollment in July 2012  [&lt;ulink linkID="1231444" linkType="Reference"&gt;1231444&lt;/ulink&gt;].  In  August 2013, a phase II  trial for atopic dermatitis was completed [&lt;ulink linkID="1271980" linkType="Reference"&gt;1271980&lt;/ulink&gt;]. In November 2012, a phase I/II  allergic asthma study started [&lt;ulink linkID="1402275" linkType="Reference"&gt;1402275&lt;/ulink&gt;]. In July 2013, the company stated that phase II activities were ongoing in food allergy [&lt;ulink linkID="1453845" linkType="Reference"&gt;1453845&lt;/ulink&gt;]. In January 2014, the company planned to submit regulatory filings in 2018 or later [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;]; in January 2015, filings for asthma were expected in 2019 or later [&lt;ulink linkID="1629087" linkType="Reference"&gt;1629087&lt;/ulink&gt;]. In January 2016, it was reported that a phase IIb trial in severe asthma had failed to demonstrate efficacy. At that time, only urticaria development was to continue and asthma as well as atopic dermatitis were no longer listed on the company pipeline [&lt;ulink linkID="1730053" linkType="Reference"&gt;1730053&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In January 2016, filings for chronic spontaneous urticaria/inducible urticaria were expected in 2020 or later [&lt;ulink linkID="1730053" linkType="Reference"&gt;1730053&lt;/ulink&gt;]. In January 2018, filings for chronic spontaneous or idiopathic urticaria were expected in 2021 [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]; in January 2019, this was still the case [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, the company planned to submit regulatory filings in 2018 or later [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;]; in January 2015, filings for asthma were expected in 2019 or later [&lt;ulink linkID="1629087" linkType="Reference"&gt;1629087&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Urticaria&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In October 2018, a randomized, double-blind, active- and placebo-controlled, parallel-group, phase III study (&lt;ulink linkID="345592" linkType="Protocol"&gt;NCT03580356&lt;/ulink&gt;; CQGE031C2303; PEARL2) was initiated  in the US, Australia, Europe, Japan and Taiwan to evaluate the efficacy and safety of ligelizumab in adolescent and adult subjects (expected n = 1050) with chronic spontaneous urticaria   who remain symptomatic despite standard of care treatment by demonstrating better efficacy over &lt;ulink linkID="2534" linkType="Drug"&gt;omalizumab&lt;/ulink&gt; (H1-antihistamines). The primary endpoint would be the  urticaria activity score (UAS) included sum of the hive severity score (HSS) and the itch severity score (ISS). At that time, the trial was expected   to complete in  April  2021  [&lt;ulink linkID="2053168" linkType="Reference"&gt;2053168&lt;/ulink&gt;], [&lt;ulink linkID="2101443" linkType="Reference"&gt;2101443&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, a randomized, double-blind, active- and placebo-controlled, parallel-group, phase III study (&lt;ulink linkID="345602" linkType="Protocol"&gt;NCT03580369&lt;/ulink&gt;; CQGE031C2302; 2018-000839-28, PEARL1)  was initiated in the US, Canada and  Europe to evaluate the efficacy and safety of ligelizumab in adolescent and adult subjects (expected n = 1050) with chronic spontaneous urticaria and who remain symptomatic despite the use of H1-antihistamines. The primary endpoint would be the absolute change from baseline in UAS7 at week 12. At that time, the trial was expected to complete in May 2021 [&lt;ulink linkID="2090844" linkType="Reference"&gt;2090844&lt;/ulink&gt;], [&lt;ulink linkID="2101443" linkType="Reference"&gt;2101443&lt;/ulink&gt;]. In August 2018, the protocol was approved in Korea [&lt;ulink linkID="2017055" linkType="Reference"&gt;2017055&lt;/ulink&gt;]. By March 2019, the trial had begun [&lt;ulink linkID="2090844" linkType="Reference"&gt;2090844&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2018, an interventional, parallel assignment, randomized, double-blind, parallel group, placebo controlled, quadruple, multicenter study, dose-finding phase IIb study (&lt;ulink linkID="329947" linkType="Protocol"&gt;NCT03437278&lt;/ulink&gt;: CQGE031C2202; 2017-004207-52) was planned to initiate in May 2018 to evaluate the efficacy and safety of QGE-031 in adolescent patients (expected n = 50) with chronic spontaneous urticaria. The trial was expected to complete in March 2020 and the primary endpoint was to determine the change in the urticaria activity score between baseline and week 24 [&lt;ulink linkID="2042811" linkType="Reference"&gt;2042811&lt;/ulink&gt;]. In August 2018, the trial was initiated in Argentina, Belgium, 	Canada, Germany, Spain, Switzerland, Taiwan, Turkey and was expected to complete in November 2020 [&lt;ulink linkID="2042811" linkType="Reference"&gt;2042811&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, an open-label,  multicenter, extension study of  phase II (&lt;ulink linkID="250357" linkType="Protocol"&gt;NCT02649218&lt;/ulink&gt;; CQGE031C2201E1; 2015-003636-13) was initiated in the US, Canada, Europe, Taiwan, Japan and Australia to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients (n = 227) who completed study CQGE031C2201.  The primary endpoint was number of participants with treatment-emergent adverse events in a time frame of 2 years. At that time, the trial was expected to complete in May 2019 [&lt;ulink linkID="2090854" linkType="Reference"&gt;2090854&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, a multicenter, randomized, double-blind, placebo, and active-controlled, phase IIb dose-finding study (&lt;ulink linkID="232754" linkType="Protocol"&gt;NCT02477332&lt;/ulink&gt;; CQGE031C2201, 2014-005559-16)  of the drug as add-on therapy to evaluate the efficacy and safety in patients (n = 382) with chronic spontaneous urticaria who are not adequately controlled by H1 antihistamines compared with &lt;ulink linkID="2534" linkType="Drug"&gt;omalizumab&lt;/ulink&gt; was expected to begin in July 2015 in the US, Australia, Canada, Germany, Greece, Japan, Russia and Spain. The study was expected to complete in March 2017 [&lt;ulink linkID="1673108" linkType="Reference"&gt;1673108&lt;/ulink&gt;]. In November 2015, the drug was listed as being in phase II development in Japan for chronic idiopathic urticaria [&lt;ulink linkID="1714789" linkType="Reference"&gt;1714789&lt;/ulink&gt;]. In January 2016, the trial was initiated also in Taiwan and the UK [&lt;ulink linkID="1673108" linkType="Reference"&gt;1673108&lt;/ulink&gt;]. In May 2018, data, presumably from this phase IIb trial, were presented at the EAACI Congress 2018 in Munich, Germany, showing a rapid onset of action, and improved and sustained efficacy compared with omalizumab [&lt;ulink linkID="2054895" linkType="Reference"&gt;2054895&lt;/ulink&gt;]. Further data were presented at the same conference. At week-12, the proportion of patients with complete hives response (HSS = 0; primary endpoint) was 30.2, 51.2, 42.4, 25.9 and 0% in ligelizumab 24, 72 or 240 mg, omalizumab and placebo groups, respectively;  indicating that the primary endpoint was achieved with ligelizumab demonstrating a dose-response relationship (p &amp;lt; 0.001). With ligelizumab 72 and 240 mg versus omalizumab and ligelizumab 24 mg, higher changes from baseline in HSS7, ISS-7 and UAS-7 were observed; the benefit in favor of ligelizumab 72 and 240 mg was sustained up to week 32 and was more pronounced in the 240 mg group. Dermatology Life Quality Index of 0 to 1 (no impact on quality of life) was achieved by substantial proportion of patients as early as week 4 in the treatment groups compared to placebo. None of the serious adverse event was considered related to ligelizumab treatment [&lt;ulink linkID="2064022" linkType="Reference"&gt;2064022&lt;/ulink&gt;]. The trial was completed in June 2017 [&lt;ulink linkID="1673108" linkType="Reference"&gt;1673108&lt;/ulink&gt;]. In September 2018, further data were presented at the 27th Annual EADV Congress in Paris, France. Ligelizumab 240 mg exhibited median time to loss of complete response of 10.5 weeks, 4 weeks each for ligelizumab 72 mg and omalizumab 300 mg, and 3 weeks for ligelizumab 24 mg. At week 20, mean changes from baseline in UAS7 for ligelizumab 24, 72 and 240 mg, omalizumab 300 mg and placebo were -15.2, -23.1 and -22.5, -18.2 and -13.6, respectively [&lt;ulink linkID="2122010" linkType="Reference"&gt;2122010&lt;/ulink&gt;]. In March 2019, further results  were presented at 77th AAD Annual Meeting in Washington DC. Sustained complete responses were reported and at the end of week 52, over 50% of patients achieved 7-day Urticaria Activity Score (UAS7) equal to zero. Throughout the one-year treatment period, complete symptom control was cumulatively experienced at least once by 75.8% of patients by the end of week 52 [&lt;ulink linkID="2126231" linkType="Reference"&gt;2126231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Atopic dermatitis&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2014, data from three double-blind, randomized placebo-controlled studies were presented at the 2014 ATS International Conference in San Diego, CA. The systemic exposure and t1/2 were observed to be ligelizumab dose-dependent. A reduction in free IgE below the quantification was observed at all dose levels of ligelizumab [&lt;ulink linkID="1557644" linkType="Reference"&gt;1557644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, a randomized, double-blind, placebo- and active-controlled, phase II study (&lt;ulink linkID="85616" linkType="Protocol"&gt;NCT01552629&lt;/ulink&gt;; CQGE031X2201; 2011-002112-84) was initiated in patients with atopic dermatitis (expected n = 30) in Germany, France and Austria, to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of ligelizumab. At that time, the study was scheduled to complete in September 2012. In August 2013, the trial was completed [&lt;ulink linkID="1271980" linkType="Reference"&gt;1271980&lt;/ulink&gt;]. In September 2013, data presumed to be from this study were presented at the 23rd ERS Annual Congress in Barcelona, Spain. Ligelizumab was well tolerated with no serious adverse events. There were reductions in free circulating IgE, FcepsilonRI, surface IgE, and skin prick test responses significantly greater and for longer than omalizumab [&lt;ulink linkID="1480952" linkType="Reference"&gt;1480952&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asthma&lt;/subtitle&gt;​&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2016, it was reported that a phase IIb study in patients with severe, uncontrolled asthma failed to demonstrate efficacy following 16 weeks of treatment when added to high-dose inhaled corticosteroids plus long-acting beta2-agonists [&lt;ulink linkID="1730053" linkType="Reference"&gt;1730053&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2015, the drug was listed as being in phase II for asthma in Japan [&lt;ulink linkID="1714789" linkType="Reference"&gt;1714789&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, data from a phase II, double-blind, randomized, placebo-controlled, multicenter study were presented at the 24th ERS Annual Congress in Munich, Germany.  There was a dose-dependent response in allergen PC15 at week 12 (primary endpoint) with ligelizumab compared with placebo.  A 3-fold higher allergen PC15 shift was observed with ligelizumab (240 mg) when compared with omalizumab, at week 12. Ligelizumab (72 and 240 mg) showed more pronounced inhibition of skin prick test response than omalizumab. Ligelizumab elicited dose-dependent changes in basophil surface IgE and FCepsilonRI receptors.  Nasopharyngitis, asthma, oropharyngeal pain, diarrhea and headache were some of the adverse events observed in the study [&lt;ulink linkID="1592377" linkType="Reference"&gt;1592377&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2012, a randomized, double-blind, placebo- and &lt;ulink linkID="2534" linkType="Drug"&gt;omalizumab&lt;/ulink&gt;-controlled, phase II trial (&lt;ulink linkID="96382" linkType="Protocol"&gt;NCT01716754&lt;/ulink&gt;; CQGE031B2201, 2012-002298-69)  started to evaluate the safety and effect on asthma control of different regimens of ligelizumab in asthma patients (estimated n = 457) in the US, Argentina, Canada, Europe, Israel, and Korea, that are inadequately controlled with inhaled steroid and beta-2 agonist therapy. At that time, the trial was expected to complete in May 2014 [&lt;ulink linkID="1402310" linkType="Reference"&gt;1402310&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, a randomized, double-blind, placebo-controlled, multiple-dose, phase I/II  trial (&lt;ulink linkID="94191" linkType="Protocol"&gt;NCT01703312&lt;/ulink&gt;; CQGE031B2203) began to evaluate ligelizumab compared with &lt;ulink linkID="2534" linkType="Drug"&gt;omalizumab&lt;/ulink&gt; in subjects (estimated n = 40) in Canada and Sweden with asthma induced by allergen bronchial provocation. At that time, the trial was expected to complete in October 2013 [&lt;ulink linkID="1402275" linkType="Reference"&gt;1402275&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;By January 2011, the drug was listed as in phase I for asthma [&lt;ulink linkID="1164001" linkType="Reference"&gt;1164001&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Bullous pemphigoid&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2013, a randomized, double-blind, placebo controlled, parallel group, phase II trial (&lt;ulink linkID="91901" linkType="Protocol"&gt;NCT01688882&lt;/ulink&gt;; CQGE031X2202) was initiated in the US, Japan, Europe and Taiwan, in patients (n = 20) with bullous pemphigoid, to assess the safety and efficacy of QGE-031. At that time, the trial was expected to complete in March 2015 [&lt;ulink linkID="1634744" linkType="Reference"&gt;1634744&lt;/ulink&gt;]. In March 2015, the trial was completed [&lt;ulink linkID="1634744" linkType="Reference"&gt;1634744&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Peanut allergy&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2011, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="81524" linkType="Protocol"&gt;NCT01451450&lt;/ulink&gt;; CQGE031A2208; 2011-000631-92) was planned in patients with peanut allergy (expected n = 110) in North America and Europe, to assess the safety and efficacy of ligelizumab. At that time, the study was expected to begin in November of that year and complete in  February 2013 [&lt;ulink linkID="1231444" linkType="Reference"&gt;1231444&lt;/ulink&gt;]. In January 2012, the study was expected to start in that year [&lt;ulink linkID="1257608" linkType="Reference"&gt;1257608&lt;/ulink&gt;]. In March 2012, the trial was planned to begin  in May 2012; however, the trial was withdrawn prior to patient enrollment in July 2012  [&lt;ulink linkID="1231444" linkType="Reference"&gt;1231444&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By December 2009, Novartis successfully conducted proof-of-concept studies on the antibody [&lt;ulink linkID="1164326" linkType="Reference"&gt;1164326&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2017, the EMA's Pediatric Committee (PDCO) adopted a positive opinion agreeing a pediatric investigation plan (PIPS) for ligelizumab for the treatment of chronic spontaneous urticaria [&lt;ulink linkID="1971224" linkType="Reference"&gt;1971224&lt;/ulink&gt;]. In June 2018, the EMA's Pediatric Committee adopted a positive opinion on modifications to a PIP for the treatment of chronic spontaneous urticaria [&lt;ulink linkID="2048363" linkType="Reference"&gt;2048363&lt;/ulink&gt;]. In November 2018, the EMA's Pediatric Committee adopted a positive opinion on compliance check  for ligelizumab for the treatment of chronic spontaneous urticaria [&lt;ulink linkID="2134764" linkType="Reference"&gt;2134764&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2090844" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-10-20T00:00:00.000Z</StatusDate><Source id="2053168" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2090844" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-10-17T00:00:00.000Z</StatusDate><Source id="2090844" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-10-20T00:00:00.000Z</StatusDate><Source id="2053168" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2019-01-30T00:00:00.000Z</StatusDate><Source id="2090844" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-10-20T00:00:00.000Z</StatusDate><Source id="2053168" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-08-01T00:00:00.000Z</StatusDate><Source id="2042811" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3612">Food hypersensitivity</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3615">Peanut hypersensitivity</Indication><StatusDate>2012-07-20T00:00:00.000Z</StatusDate><Source id="1231444" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate><Source id="1730053" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20318">Tanox Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1005">Unidentified indication</Indication><StatusDate>2009-05-21T00:00:00.000Z</StatusDate><Source id="1164321" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3615">Peanut hypersensitivity</Indication><StatusDate>2011-10-12T00:00:00.000Z</StatusDate><Source id="1231444" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2011-01-27T00:00:00.000Z</StatusDate><Source id="1164001" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2015-06-11T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2015-06-11T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2015-06-11T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2015-06-11T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2015-06-11T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1271980" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1402310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1402310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1402310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1402310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3612">Food hypersensitivity</Indication><StatusDate>2013-07-17T00:00:00.000Z</StatusDate><Source id="1453845" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2015-11-16T00:00:00.000Z</StatusDate><Source id="1714789" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1402310" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="6187">Bullous pemphigoid</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1402275" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2012-11-30T00:00:00.000Z</StatusDate><Source id="1402275" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2016-01-05T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2016-01-05T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2016-01-05T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2016-01-05T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2015-11-16T00:00:00.000Z</StatusDate><Source id="1714789" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2016-01-05T00:00:00.000Z</StatusDate><Source id="1673108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="340">Urticaria</Indication><StatusDate>2018-08-20T00:00:00.000Z</StatusDate><Source id="2017055" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1005">Unidentified indication</Indication><StatusDate>2009-05-21T00:00:00.000Z</StatusDate><Source id="1164321" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2010-01-26T00:00:00.000Z</StatusDate><Source id="1164326" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="EU">EU</Country><Indication id="340">Urticaria</Indication><AwardedIndication>Treatment of chronic spontaneous urticaria </AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-11-13T00:00:00.000Z</MileStoneDate><Source id="2134764" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01006"><Name>Immunoglobulin E</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="133788" title="Novartis to develop Tanox' QGE-031 for the treatment of allergic diseases including asthma "/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>